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Lyda, Jennene, M.S., August 22th 2014
Toxicology
An Environmental Toxin model of Parkinson’s Disease: The Fruit Fly
Chairperson: Fernando Cardozo-Pelaez, Ph.D.
Parkinson’s disease (PD) is the second most common neurodegenerative
disorder with no known specific cause; although genetic risk factors and/or
environmental exposure are thought to be involved. The etiology of PD is
currently unknown, although the combination of non-genetic components such as
environmental exposures, the accumulation of exposure, and gene-environment
interactions are thought to play a major role. However, despite this knowledge it
is important to develop better models that parallel PD pathophysiology to further
understand the mechanisms underlying dopaminergic neuron (DaN) damage.
The use of mammalian models to study the degenerative processes in PD has
been the most common approach. However, Drosophila melanogaster use has
proven to be important to identify the physiological role of PD associated genes,
and to identify pathological mechanisms of environmental toxins associated with
sporadic PD.
The synthetic drug MPTP (1-methyl- 4-phenyl-1,2,3,4tetrahydropyridine) has been extensively used to generate animal models of PD.
MPTP is the most used toxin model with highly reproducible effects in mice and
non-human primates, and its use is a requirement for the development of new
therapeutic approaches. However, MPTP neurotoxicity has not been reported in
D. melanogaster. Results from the studies presented in this thesis show that
Drosophila exposure to MPTP may be a useful model of PD, as evidenced by:
loss of brain DA, reduction in tyrosine-hydroxylase positive neurons and inhibition
of mitochondrial complex I. Thus, taken together this recapitulates the
mammalian model
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CHAPTER ONE: INTRODUCTION
This study describes the characterization of an MPTP-toxin induced model
of Parkinson’s disease in Drosophila melanogaster, or fruit fly. The introductory
chapter will: 1) Present an overview of PD and current therapies; 2) Discuss PD
genetics and the etiology of the disease; 3) Explain the pathophysiology of PD
and the role of mitochondria; and 4) Provide information on current models of PD
and how they contribute to our understanding of PD.
Overview to Parkinson’s Disease
Parkinson’s Disease (PD) is the second most common neurodegenerative
disease after Alzheimer’s Disease (AD). Currently, seven to ten million people
worldwide are diagnosed with PD with a higher percentage of patients being
older than 65 years of age and this percentage is estimated to continue to rise
(Parkinson’s disease Foundation). Clinically, several symptoms are manifested
in PD that can be classified as motor and non-motor. Motor symptoms include:
resting tremor, rigidity, bradykinesia, and postural instability.

These motor

symptoms are the most noticeable and are diagnosed based on at least one of
these symptom criteria: muscular rigidity, a resting tremor of at least 4-6 Hz,
patient history, and exclusion of other disease symptoms (Worth 2013). Nonmotor symptoms can accompany motor symptoms and are often the most
impacting on the quality of life in patients, which include: autonomic insufficiency,
cognitive impairment, and sleep disorders. Non-motor symptoms are unique in
that they may be evident earlier in the disease and before motor symptoms.
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Demonstrating their impact on quality of life of patients, these non-motor
symptoms are the major determining factor for assisted care of patients.
The pathophysiology of this chronic progressive disease is characterized
by the loss of dopaminergic neurons in the substantia nigra with the presence of
Lewy bodies (LBs), which are proteinaceous, α-synuclein-containing inclusions
within the surviving dopaminergic neurons (DaN).

α-Synuclein is a normal

endogenous protein in the brain that has a suggested role in synaptic vesicular
trafficking (Overk and Masliah 2014).

Although much has been done to

understand the mechanisms underlying the pathophysiology, the cause of PD is
still unknown. The most current hypothesis suggests that interplay between
genetic predispositions and environmental exposures underlay cause on the
onset of idiopathic PD.
The diagnosis of PD still relies on clinical skill of the patient’s physician to
make a diagnosis based on the UK PD brain bank diagnostic criteria (Dickson et
al. 2009). There are currently no selective biomarkers to make a definitive
diagnosis, let alone, before symptoms are overt. As mentioned before, diagnosis
is based on the presence or absence of bradykinesia (the slowness of voluntary
movement), and at least one of the other motor symptoms listed previously. The
diagnostic standard also includes exclusion criteria (i.e history of strokes, head
injury, etc.), additional supportive criteria (i.e Levodopa response, disease
progression, etc.), and neuropathological presence of neuronal loss and LBs
(Obeso et al. 2010). Although, despite neuronal loss and LBs having a part in
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diagnosis, there is no definitive protocol for this type of assessment thus
generating a need for better diagnostic imaging of the brain and biomarkers.
Currently PD is incurable and it progresses at different rates depending on
the individual.

There are several treatments for patients with PD, but it is

important to note that these treatments only treat the symptoms of PD rather than
tackling the pathophysiology causing the neuronal loss. Treatment for PD can be
divided into two types based on the symptoms they are treating, motor and nonmotor. The timing of initiation of these therapies is still debated. Most patients
are left untreated until developing a disability that impacts their quality of life,
whereas some studies report dopaminergic drug therapy before disability
presence showing improvement of quality of life (Grosset et al. 2007).
The most common drug treatment for motor symptoms is Levodopa, or Ldopa. In combination with a dopamine carboxylase inhibitor, L-dopa remains the
most efficacious treatment for PD motor symptoms for the last 60 years (LeWitt
2008).

L-dopa is the precursor for dopamine, therefore is effective by

replenishing dopamine in surviving neurons. One of the major side effects of Ldopa treatment is L-dopa induced dyskinesia’s (LIDs), which involve dramatic
involuntary chorea movements that can be more debilitating to patients than the
motor symptoms themselves. Typically L-dopa therapy is not used in patients
under the age of 50 due to a reduced response consistency over time of use, but
it is still a first line of treatment in patients of all ages (Ku and Glass 2010).
Dopamine agonists (DAs) are another used group of drugs intended to
activate the dopamine receptor in the absence of dopamine for treatment of
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motor symptoms. These sets of drugs are typically used as a first line of defense
for early PD, similar to L-dopa. Also similar to L-dopa, DAs are associated with
side effects termed impulse control disorders (ICDs).

ICDs occur in 17% of

patients that can range in symptoms including hypersexuality, compulsive
gambling, shopping and eating (Voon, Mehta, and Hallett 2011).
Monoamine oxidase B (MAO-B) inhibitors, which inhibit the enzymatic
breakdown of neurotransmitter amines (dopamine), have limited use for
treatment of PD but, are found to reduce mild tremor symptoms in patients.
Along with the lesser-used MAO-B inhibitors, anticholinergic drugs are
occasionally used for patient’s symptoms predominantly having tremors,
although their efficacy is hampered by its neuropsychiatric side effects in some
patients.

Pharmacological therapies for non-motor symptoms mentioned are

minimal, thus leaving a need for development strategies to abate these
symptoms.
In most patients, the combinational therapies of drugs discussed above
are used for individualized treatment in patients. As the disease progresses,
pharmacological therapy is less effective leaving exploration of other forms of
treatment including non-pharmacological therapies.

Non-pharmacological

therapies include options such as deep-brain stimulation (DBS) and physical
therapy.

DBS is generated by trends of high-frequency electrical impulses

delivered to the subthalamic nucleus or globus pallidus interna mitigating the side
effects of medications or allowing for reduction of medication dose (Carron et al.
2013). Despite these treatments, there is still a need for therapies aiming for
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neuro-protection and neuronal restoration, and the development of models for
capturing the disease pathology and symptoms to evaluate such therapeutic
approaches.
Genetics of Parkinson’s Disease
Monogeneic inheritable forms of PD are thought to account for less than 10% of
all cases and of these cases only a few follow Mendelian inheritance patterns.
Despite representing a smaller portion of PD cases, familial inheritance studies
have revealed 15 PD loci (PARK 1-15) with 11 of these PARK loci that have
been described (TABLE 1). In addition to familial genes known to cause PD
there are also known genes associated with sporadic PD (of no known cause)
(TABLE 2) as well as variants of each of these genes that can also contribute to
disease and/or individual susceptibility.
Familial PD genetics can be divided into two groups: autosomal dominant
loci and autosomal recessive loci. Autosomal dominant loci include mutations in
the α-synuclein gene (SNCA), PARK1 and PARK 4 and LRRK2/PARK8 (Lesage
and Brice 2012). There are also other dominant genes described; yet, these are
controversial and have not been replicated (UCHL1/PARK5), GRB10- interacting
GYF protein 2 (GIGYF2/PARK11), Omi/Htra2 (PARK13). The SNCA gene codes
for a component of the amyloid precursor protein and is thought to be
responsible for membrane trafficking and synaptic signaling and when
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TABLE 1. 15 PD loci associated with familial inheritance

Adapted from (Coppedè 2012)
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TABLE 2. Parkinson’s Disease-associated genes

Adapted from (Abou-Sleiman, Muqit, and Wood 2006)
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present with a mutation causes functional and structural abnormalities and the
formation of LBs (Puschmann 2013). Mutations of SNCA can be either missense
or point-mutations with a mutation frequency of about 1% (Irwin, Lee, and
Trojanowski 2013).

Phenotypically, SNCA mutations resemble sporadic PD

patients with the presentation of earlier onset and atypical features, including
cognitive decline, psychiatric problems and autonomic dysfunction (Singleton,
Farrer, and Bonifati 2013).
Another common autosomal dominant mutation is in LRRK2, which is
associated with young-onset familial (~10%) and late-onset sporadic PD (~2%)
(Krüger 2008). LRRK2 protein’s role in dopaminergic cell death is unknown but it
is thought to be due to a decrease in its kinase activity (Wickremaratchi, BenShlomo, and Morris 2009).
Genes associated with autosomal recessive forms of PD include: Parkin:
PARK2, PTEN-Induced Putative Kinase 1 Gene (PINK-1): PARK6, DJ-1: PARK7,
and ATP13A2 Gene: PARK9. Typically, PD cases due to these genes appear in
offspring of unaffected parents due to their inheritance pattern, therefore
sometimes determined sporadic due to its lower frequency (Lin and Farrer 2014).
Typically these alleles result in loss of function due to inactive protein and/or
absence of protein synthesis.
Parkin mutations account for the majority of autosomal recessive cases in
patients and there are approximately 170 different mutations possible on the
chromosome (Mata, Lockhart, and Farrer 2004).

Parkin mutations are

characterized by early onset of disease without the presence of LBs. Parkin is
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thought to be responsible for mitochondrial-induced apoptosis through
unregulated release of cytochrome c.
PTEN-induced putative kinase 1 (PINK-1) is also an autosomal recessive
mutation on a different chromosome from the Parkin mutations. The PINK-1
mutations are responsible for mitochondrial deficits, therefore leading to
mitochondrial dysfunction.

Typically, PINK1 is involved in mitochondrial

maintenance participating in an upstream pathway in mitochondrial autophagy
(Kawajiri et al. 2011).

Similar to PINK-1, which responds to mitochondrial

alterations, DJ-1 (PARK7) responds to changes in oxidative stress environment
for mitochondrial protection. This response action causes DJ-1 to bind to PINK1
to promote degradation by the ubiquitin proteasome system (UPS) by damaged
parkin proteins. Mutations in the ATP13A2 Gene (PARK 9) lead to pathologies
that resemble idiopathic PD. The protein coded by PARK 9 is thought to be
involved in homeostasis of manganese (Chesi et al. 2012). The other PARK loci
are thought to be mainly involved in the UPS system and disruption of this
protein homeostatic pathway.
Overall, genetics play an important role in PD pathology and have helped
our understanding of the pathological pathways linked to the neurodegenerative
process. As shown in Figure 1, the interplay between environment and genetics
is the basis of the current hypothesis of etiology of PD pathology. However,
whether it is a specific environmental agent or family of agents; as well as which
genes are more relevant for the development of the idiopathic form of PD needs
to be fully determined.

	
  

In addition to genetics, epigenetic mechanisms are
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thought to have a key role in modulating the risk of PD development; this is
supported by findings of differential methylation patterns in some of the genes
discussed above (e.g LRRK2, SNCA).
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FIGURE 1

Adapted from (Krüger 2008)
Figure 1. Penetrance of PD and susceptibility factors
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Etiology of Parkinson’s Disease
The exact etiology of PD is unknown; however, there are hypothesis about
what contributes to the different forms of the disease. One of the hypotheses
suggests a major genetic component for the development of early-onset forms,
while the late-onset forms are mostly due to environmental factors. It is believed
that the link between these two types of hypothesis is at the root of the cause
and the mechanism linked to the dopaminergic neuronal death. Three common
endogenous factors, dopamine, alpha-synuclein, and calcium, are linked to five
different mechanisms of DaN degeneration. The first mechanism involves
generation of oxidative stress through the oxidation of cytosolic dopamine. The
second mechanism is initiated by the release of dopamine due to synaptic
vesicle permeabilization from mutations and/or excessive alpha-synuclein.

The

third mechanism is through dopamine binding to alpha-synuclein protofibrils,
allowing them to be a persistent toxic species. The fourth proposed mechanism
is driven by increased intracellular calcium leading to the dysfunction of the
mitochondria. The fifth mechanism is the inhibition of the lysosomal degradation.
Figure 2 illustrates the possible interactions between endogenous factors,
environment, and genes, with the possible outcomes leading to pathology seen
in PD. This best summarizes the most current hypothesis for the etiology of PD,
taking into account all these factors and how they may interplay. Thus,
determining a direct explanation or identifying a single cause, is a complicated
endeavor.

	
  

12	
  

FIGURE 2
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Adapted from (Fahn 2010)
Figure 2. Etiologic Factors Involved in Parkinson’s disease
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Role of Mitochondria in Dopaminergic Cell Death
Mitochondrial dysfunction has been implicated as a key component to PD
pathogenesis. Additionally, the discovery of toxins such as, MPTP (1-methyl- 4phenyl-1,2,3,4-tetrahydropyridine)

has

further

implicated

the

environmental toxins and that of mitochondria dysfunction in PD.

role

of

The link

between mitochondria dysfunction and PD was first suggested when it was
shown that patients with PD had decreased complex I activity in the substantia
nigra, skeletal muscle and platelets (Mizuno et al. 1989), and further supported
by identifying that the major mitochondrial Complex I inhibition is a common
mechanism linked to dopaminergic toxins (Banerjee et al. 2009).
MPTP enters the brain by crossing the blood-brain barrier where it is converted
to MPP+ by the enzyme monoamine oxidase B.

MPP+ then binds to the

dopamine transporter and is transported into neurons. Inside the neurons MPP+
has a high affinity for the complex I of the electron transport chain (ETC),
inhibiting respiration. This inhibition of the ETC induces a build-up of free radical
production, oxidative stress, decreased ATP production, subsequent release of
intracellular calcium, and excitotoxicity. Furthermore, it has been shown that
MPP+ releases dopamine leading to increased oxidative stress (Carta, Carboni,
and Spiga 2013).
The complete picture of mitochondrial involvement with PD began after
the discovery of familial genes of PD. As mentioned in the section discussing
genetics and PD, many of the familial genes associated with PD have some role
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in physiological pathways that directly or indirectly are associated with the
mitochondria; thus, inferring that normal mitochondria function is a major factor in
promoting DaN viability (Chesselet and Richter 2011). Figure 3 depicts the
accepted mechanism for dopaminergic neurotoxicity associated with MPTP,
while Figure 4 illustrates the purported role in mitochondrial dysfunction and
oxidative stress of some of the genes implicated in familial forms of PD.
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FIGURE 3

Adapted from (Vila and Przedborski 2003)
Figure 3. MPTP Inhibition of Mitochondrial complex I
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FIGURE 4

Adapted from (Abou-Sleiman, Muqit, and Wood 2006)
Figure 4. Genes Involved in Mitochondrial Dopaminergic cell death
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Toxin-Induced Models of Parkinson’s Disease
The current knowledge and advancements in the field of PD can be attributed to
the use and discovery of PD models. Although there are many models available,
as will be discussed, there are unique characteristics linked to toxicological
mechanism, exposure, and progression of damage that would make a model
more suitable than others to answer a specific question (Beal 2001). First, the
main characteristic of PD pathology is the gradual loss of dopaminergic neurons
and the age-dependent formation of LBs. For any model, a loss of dopamine of
about 50%, should be detectable by biochemical and neuropathology. Second,
the model should link dopamine loss and motor-deficits; thus, reenacting the
classical hallmarks of the disease (bradykinesia, resting tremor, and postural
rigidity) (Blesa et al. 2012).

Finally, tying the model to a single mutation is

important to discover disease etiology. Currently, there is not a single model that
combines the major risk factors of PD. A generation of such model may allow for
shorter time for evaluation of experimental therapies and to assess the effect of
the aging process.
The use of dopaminergic toxins in vertebrates is the most common
approach to model the neuronal loss in PD. Toxin-induced models include: 6hydroxydopamine (6-OHDA), rotenone, and MPTP. Figure 5 depicts the most
accepted mechanism for each of these toxin-induced models. 6-OHDA is used
in rats, mice, and primates by direct injection into the substantia nigra, usually
generating a unilateral lesion (Harvey, Wang, and Hoffer 2008). Although, LBs
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are not present, there is a loss of targeted DaNs that can lead to a reduction in
motor abilities (Tieu 2011).
Rotenone is a pesticide that is still used in the fishing industry today.
Rotenone is a selective inhibitor of mitochondrial complex I. Chronic treatment
with rotenone has replicated the specificity of dopaminergic nigral neuron loss in
rodents, and is the only toxicological model to generate LBs.

This model,

however, is not widely used due to the variability and lack of consistency of the
neuropathological changes (Lapointe et al. 2004)(Zhu et al. 2004).
MPTP is the most common used toxin to generate a PD model.

As

discussed in the previous section, it was one of the first models to link the
inhibition of mitochondria complex I and PD. Although several animal species
have been treated with MPTP to recapitulate the model (sheep, dogs, guinea
pigs, cats, mice, rats, and monkeys), the MPTP-monkey model is still the
standard for testing of therapeutic interventions (Carta, Carboni, and Spiga
2013). Both monkeys and mice treated with MPTP have selective progressive
loss of nigrostriatal DaN, reproducible motor deficits, but no LBs (Tieu 2011).
Table 3 (excluding paraquat/maneb) summarizes the current toxininduced models and what characteristics are present in each one. Having these
models as the current standards has been beneficial, although the need for a
better model that is cheaper, faster to screen therapeutic interventions, and
accessible is necessary.
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Figure 5

Adapted from (Abdel-Aal, Assi, and Kostandy 2011)
Figure 5. Mechanisms of Toxin-Induced Models of Parkinson’s disease
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Table 3. Toxin-Induced Models of Parkinson’s disease

Adapted from (Tieu 2011)
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The use of Drosophila melanogaster as a neurodegenerative model
Using Drosophila melanogaster as a model for neurodegenerative processes has
become increasingly popular, especially in the field of PD. The current models of
PD do not include all the major risk factors linked to the pathological processes
observed in the disease, whereas Drosophila models are amiable to incorporate
most of them and may fill this need (Guo 2012). The use of an invertebrate
model has many advantages over traditional vertebrate models, such as: short
lifespan, ease of genetic manipulation, and a conserved DA neurotransmitter
system.

The drosophila genome has limited redundancy and is 77%

homologous to humans (Rubin 2011).

Therefore, studying familial genes

associated with PD (DJ-1, PINK1, PARKIN, LRRK2, and VPS35) and their role in
pathogenesis in the fly is possible.
In addition to genetic forms of PD, toxin-induced models of PD in
Drosophila are becoming useful tools. Several studies have looked at rotenone
and paraquat (PQ) (a proposed mitochondrial complex I inhibitor) in Drosophila
to investigate susceptibility of PD genetic models and its role in neuronal cell
death (Botella et al. 2009). Not only do these models induce loss DaNs, but also,
there is evidence of behavioral and histological changes, completing the
pathological picture of PD (Trinh et al. 2010). Despite studies in Drosophila
examining rotenone and paraquat, as models, there are no studies with MPTP in
drosophila.
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The hypothesis tested and presented is that wild-type Drosophila
melanogaster will be susceptible to MPTP and will generate a robust model with
classical signs of PD pathology as defined by loss of dopamine, tyrosine
hydroxylase-positive neurons, and motor behavior deficits. Therefore, we want
to

determine

how

MPTP,

implicated

in

other

PD

models,

impacts

pathophysiology and toxicity in Drosophila in the following two aims:
Specific Aim 1: To define the time- and dose-course susceptibility to MPTP
dopaminergic neurotoxicity in Drosophila.
Specific Aim 2: To correlate inhibition of mitochondrial Complex I with loss of the
dopaminergic system in Drosophila.
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CHAPTER TWO: AIM ONE
Defining the dose susceptibility to MPTP dopaminergic neurotoxicity in
Drosophila melanogaster: Analysis of PD pathological markers after toxin
exposure
Abstract
Drosophila melanogaster has become a useful tool for assessing models of PD.
The use of toxin-induced models, such as rotenone and paraquat, has been
investigated in Drosophila, but MPTP has not been tested.

This chapter

describes a method for MPTP exposure in Drosophila and investigates
biochemical and pathological markers associated with PD. Exposure to MPTP
reduced dopamine in brains of male flies and altered behavior assessed by
startle-induced negative geotaxis.
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Introduction
Models of Parkinson’s disease (PD) are important in the discovery of the
pathophysiology of the disease.

Although there are several animal models

looking at familial genetic mutations that have roles in the disease pathways,
models portraying idiopathic PD, which are the majority of disease cases, are
critical in discovery of mechanisms.
Drosophila melanogaster (fruit fly) has been increasingly useful in PD
modeling. More specifically, Drosophila has been used for investigating rotenone
and paraquat (PQ), both of which are commonly used for modeling idiopathic PD.
Recently, rotenone has been used in several studies examining PD pathology
markers including: histology and behavioral assessment (Hosamani, Ramesh,
and Muralidhara 2010). PQ exposure in Drosophila has also been established in
some studies for acute and chronic exposure (Rzezniczak et al. 2011) (Lawal et
al. 2010). Despite both of these models showing pathologic markers seen in PD,
there are several inconsistencies with both the rotenone and paraquat models in
other animals used (Vila and Przedborski 2003). These types of inconsistencies
include: low percentage of rats exposed showing nigrostriatal lesions, rotenone is
specific to rats and does not work in other animal models, and there are no
reported

human

toxicity

exposures

resulting

in

PD

(Nussbaum

and

Polymeropoulos 1997). Similarly, results with paraquat, remain inconsistent due
to conflicting reports in relationship to the susceptibility of dopaminergic neurons
after exposure, or whatever PQ combination with maneb (manganese
ethylenebisdithiocarbamate) is a more effective model (Thiruchelvam et al. 2000)
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(Thiffault, Langston, and Di Monte 2000).

MPTP has been used in animal

models of genetic forms of PD, contributing to the identification role(s) these
genes play in pathophysiology.

Therefore, the most common and highly

researched and reproducible toxin-induced model, MPTP, should be developed
in the fruit fly.
The following study describes an analysis of PD pathological markers in
Drosophila males after MPTP exposure. Although Drosophila has been used as
a model for rotenone and paraquat toxicity, the MPTP model has yet to be
investigated.

Optimization of the CAFÉ assay with MPTP was achieved by

spectrophotometry and measurement of consumption. The method described
here was used to analyze dopamine in brain of flies exposed to increasing
concentrations of MPTP and to assess behavior and tyrosine hydroxylase
expression after exposure. Our results indicate that acute MPTP exposure leads
to a dose-dependent loss of dopamine, a trend in reduction of TH-positive
neurons and alterations in motor behavior in flies. Thus, these results indicate
that the MPTP toxin-induced model in Drosophila melanogaster is a useful tool to
use for pathophysiology in PD.
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Materials and Methods
Chemicals and Reagents
All reagents were purchased from Sigma Aldrich unless otherwise
indicated (St Louis, MO). MPTP were made fresh for each exposure with 5%
sucrose w/v.
Drosophila Stocks, Husbandry, and transgenics
D. melanogaster wild-type (Canton-S) was obtained from the Bloomington
Stock center (Bloomington, IN). The flies were reared on agar medium (1%, w/v
brewer’s yeast; 2%, w/v sucrose; 1%, w/v agar; 0.08%, v/w Tegosept®) at
constant temperature and humidity (23°C; 60% relative humidity, respectively).
The flies were reared in 16 x 100 mm vials containing approximately 5 mL of
medium at constant temperature, humidity (60%) and under 12h dark/light cycle.
All experiments were performed with the same WT Canton-S strain except for
Immunohistochemistry.
Crosses to generate the TH-Gal4:20xUAS-6xGFP (green fluorescent
protein) flies were set up under standard conditions at 25° C.

Male flies

containing the TH-Gal4 UAS transcript were mated with females containing the
20x-6xGFP insert, then pupae were collected into isolation vials.
Drosophila MPTP exposure
The capillary feeder method (CAFE) CAFÉ assay used for exposure was
adapted from JA, et al. 2007 (Ja et al. 2007). The exposure model used was
similar with two chambers.

The inner chamber, containing the flies, was

composed of a 25 cm vial with perforated lid for air and water exchange from the
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outer chamber, a 1000 mL beaker with 20 cm distilled water, and additional holes
for capillary tube insertion. Capillary tubes at 40 cm length from World Precision
Instruments (Sarasota, FL) (cat. #4878) were filled by capillary action with liquid
and inserted into the inner vial lid with an additional layer of mineral oil to prevent
evaporation. All exposures (MPTP or sucrose control) were conducted for 24
hours in a 25°C room. After each 24-hour exposure, flies were placed back into
isolation vials containing normal food medium for 24 hours before analyses. All
exposures were done on 5-10 day old males including flies for immunohistology.
Brain dopamine via HPLC-ED
For sample preparation, fifteen 5-10 day old adult male flies were anesthetized
with CO2, and then transferred to cold phosphate buffer saline (PBS) preceding
dissection. Brains were dissected in cold PBS by gentle forceps manipulation
under a dissecting microscope, and then transferred to a 1.5 ml microcentrifuge
tube containing 100 µL perchloric acid (0.05 M) with 30 ng/mL DBA (internal
standard). On ice, brains were homogenized using a hand-held sonicator and
centrifuged for 15 minutes at 4°C at 14,000xg.
For reverse-phase high liquid chromatography (rp-HPLC) measurement of
dopamine, a modified rp-HPLC protocol for catecholamine measurement was
used as described earlier (F. Cardozo-Pelaez et al. 1999) (Fernando CardozoPelaez, Cox, and Bolin 2005). Chilled fly brain homogenates were centrifuged
and 50 µl of supernatant fluid was eluted through a 250 × 4.6 mm C18 column
(Agilent Technologies Santa Clara, CA). The mobile phase consisted of
water:acetonitrile (9:1, vol/vol) containing 0.15 M monochloroacetic acid, 0.12 M
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sodium hydroxide, 0.60 mM EDTA, and 1.30 mM sodium octyl sulfate. The flow
rate was kept at .8 mL/min (ESA Model 582 Solvent Delivery Module,
Chelmsford, MA) and the column eluent was analyzed with an electrochemical
detector (ESA Model 5600A CoulArray Detector, 3 ESA Model 6210 four channel
electrochemical cells, Chelmsford, MA -50, 0, 100, 200, 300mV). All RP-HPLC
data were recorded stored and analyzed using CoulArray for Windows
32Software (ESA Chelmsford, MA). DA was monitored at 300mV. The ratios of
peak height measured in Nano amperes (nA) produced by DA to the peak height
(nA) produced by DBA (internal standard) in the samples were used to obtain the
analyte levels from a calibration curve. Data was expressed as micrograms of
analyte per brain (µg/brain).
Immunohistology & Confocal Imaging
For immunohistochemistry; after cuticle was removed, the brains were fixed in
4% paraformaldehyde. Confocal microscopy image processing was performed
using a Olympus IX81 confocal microscope and Fluoview FV1000 viewer and
application software.

Antibody dilutions were as follows: rabbit anti-Tyrosine

Hydroxylase 1:200 (Abcam) and Goat anti-rabbit 594 1:200 (Abcam). Images
were acquired at a resolution of 1024 pixels. The counting of DA neurons labeled
with TH:GFP and 594 labeling were tracked through confocal Z-stacks.
Startle-Induced Negative Geotaxis
To assess locomotor climbing activity, we transferred into empty plastic vials 3050 male flies that had been exposed to MPTP or 5% sucrose were transferred
into empty 50 mL conical tubes. Flies were allowed to acclimate in the vial for 15
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minutes before the test began. The vials were tapped to startle all flies to the
bottom and then the number of flies climbing up to the top quarter (7cm) of the
vial within a 15 second period, were counted. Each vial was used for three
consecutive measurements, allowing for 5 minutes rest period, with a total of
~100 flies per treatment group assessed. This method was designed similarly to
previous behavioral tests (Ali et al. 2011) (Nichols, Becnel, and Pandey 2012).
Statistical Analysis
All data were analyzed using Microsoft Excel and Prism 5 software. The t-test
was implemented when comparing just two data groups where significance was
p-value > .05. For comparison of multiple groups, ANOVA was used to
determine significant differences between each group with significance of p-value
>.05.

	
  

36	
  

Results
Establishment of the CAFÉ assay
The first set of experiments were designed to test whether flies would consume
MPTP hydrochloride dissolved in 5% (w/v) sucrose from the capillary. Typically,
fruit flies are attracted to sugar containing medium, therefore it remained a
question to whether there would be an aversion and preference for just the
sucrose control compared to sucrose containing MPTP hydrochloride.

First,

green food color was added to each sucrose or MPTP solution in capillary tubes
for the 24 hour exposure period. We previously, by spectrophotometry, identified
the maximal absorbance by spectrophotometry for the green food coloring added
(Figure 6). Using the maxima wavelength (630 nm), we compared the amount of
liquid intake between flies exposed to sucrose or sucrose/MPTP mix. Figure 7
shows evaluation of liquid intake, as determined by the amount of green color
present in sucrose alone (Figure 7A) or sucrose/MPTP mix (Figure 7B) and
quantitative assessment by absorbance at 630 nm of extracts from whole flies
after exposure to 5% sucrose or 12 mM MPTP (Figure 7C). There is no visual or
quantitative difference in liquid consumption. A secondary assessment was done
by measuring amount of liquid consumed in a period of 24 hours at 0, 24, or 36
mM MPTP. Lack of statistical difference among the groups (Figure 8) indicates
that the level of MPTP is not adverse to the Drosophila melanogaster
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FIGURE 6
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Figure 6. Visual spectral analysis of Green Dye
Maximum absorbance was determined for green dye. Each absorbance was
measured by spectrophotometer to determine the wavelength for maximum
absorbance.

630 nm was the maximum to be used for further consumption

analysis.
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FIGURE 7

Figure 7. Comparison of CAFÉ consumption during exposure to MPTP and
Sucrose
Comparison of 5% sucrose and MPTP (36 mM) and just 5% sucrose liquid was
investigated to determine whether flies were not consuming less of the MPTP
containing liquid.

Green dye was added to each control and test liquid and

photos were taken after CAFÉ assay exposure showing consumption of both
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liquids (A and B). 100 flies were crushed in PBS and absorbance was measured
at 630 nm in duplicate. There was no statistical difference found between the
control (5% sucrose) and test liquid (MPTP with sucrose).
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FIGURE 8

Figure 8. Volume consumption in capillary tubes during CAFÉ assay
exposure
Further validation of CAFÉ assay exposure with MPTP for the two highest
concentrations used of MPTP.

No statistical difference was found between the

control group and either of the exposures (24 mM & 36 mM) (n=5).
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Assessment of Brain Dopamine Levels after Exposure to MPTP
In order to determine whether MPTP is toxic to DaN, flies where exposed to 3
mM, 6 mM, 12 mM, 24 mM, or 36 mM MPTP by the CAFÉ assay.

Brain

homogenates from the different exposure groups were analyzed via rp-HPLCECD to determine the amount of dopamine per fly brain (n=5). Figure 9 is a
representative chromatogram for dopamine analysis indicating the peak for
dopamine and the internal standard. Levels of dopamine in brain homogenates
were obtained by comparing the response in the extract to responses obtained
by known amounts of dopamine. In Figure 10, the amount of dopamine per fly
brain for each concentration of MPTP is represented with 5% sucrose as control.
We established that 5% sucrose was suitable for a control because no difference
in dopamine levels was found when comparing to normal food 24-hour exposure
(Figure 11).
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FIGURE 9

Figure 9. Chromatogram profile for Dopamine
Chromatographic profile for Dopamine and Internal Standard (DBA), detected in
channels set at 300 mV.
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FIGURE 10
FIGURE 10
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Figure 10. Dopamine levels in brain after exposure to MPTP

Figure 10. Dopamine levels in brain after exposure to MPTP
Levels of Dopamine represented as picogram (pg) DA per fly brain after CAFÉ
Levels of Dopamine represented as pictogram (pg) DA per fly brain after CAFÉ
assay exposure to 3 mM, 6 mM, 12 mM, 24 mM, and 36 mM MPTP in WT male
assay exposure to 3 mM, 6 mM, 12 mM, 24 mM, and 36 mM MPTP in WT male
flies compared to 5% sucrose as control (A). Although all groups exposed
showed a reduction in DA compared to control, 36 mM and 24 mM

!
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concentrations had the greatest significant difference.

In (B), values are

expressed as percent DA loss. The greatest percent loss was seen in 24 and 36
mM MPTP exposures. Data expressed as mean ±SEM (n=5 ***p< .005 **p<.05)
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FIGURE 11

Figure 11. Dopamine levels from 5% sucrose 24-hour exposure compared
to food control
Dopamine levels represented as % change when comparing CAFÉ assay 5%
sucrose exposure vs. normal food control. No statistical difference was found.

	
  

46	
  

Tyrosine-Hydroxylase labeling in Drosophila brain
To test whether changes in dopamine levels were due to loss of DaN, we
performed immunohistochemistry for tyrosine hydroxylase (TH) in fly brains
exposed to 24 mM MPTP. Figure 12A shows the confocal images taken from
sucrose exposed or 24 mM exposed fly brains expressing TH by the Gal-4 driver
and the quantification of TH-expressing neurons for each group.
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FIGURE 12

Figure 12. Tyrosine hydroxylase Immunohistochemistry after MPTP
exposure
Flies brains expressing GFP labeled Tyrosine Hydroxylase (Green) by the Gal-4
UAS system compared with rabbit anti-Tyrosine hydroxylase antibody labeling
(red). Neurons were counted in sucrose (A and B) control and compared to
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MPTP exposed flies (C and D). The average of three separate brain images was
calculated.
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Behavior after exposure to MPTP
Because motor impairment is a direct symptom of PD and being present in other
MPTP models, we employed the startle-induced negative geotaxis assay to
assess whether there was impairment in climbing to MPTP exposed flies
compared to untreated flies (Figure 13). Typically, flies without impairment would
climb towards the light source after being startled to the bottom; therefore most
flies would climb above 7cm in the conical tube.
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FIGURE 13

A.

Pre & Post Exposure Negative Geotaxis
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Figure 13. Startle-Induced Negative geotaxis of MPTP exposed flies
Behavior analysis of flies after MPTP exposure compared to sucrose control.
Flies were counted before and after exposure. Percent flies above 7 cm was
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determined by counting the number of flies that climbed above 7 cm to the total
number of flies. Percent flies above 7 cm increased after exposure to MPTP for
all exposure, including control when compared to pre-exposure groups (A). Only
the 36 mM MPTP dose had a significant increase in climbing activity compared to
control (B).
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Discussion
The MPTP-toxin induced toxicological PD model has never been investigated in
Drosophila melanogaster.

Until now, there has not been a model method

reported to expose flies to MPTP. This may be due to MPTP’s exposure risk
concern and precautions that are required when used in other animal models.
The current toxin models (rotenone and paraquat) analyzed in Drosophila do not
have a complete analysis of Parkinson-like assessments that extend beyond
behavior and immunohistology, or both. Here, we show evidence of a reduction
in dopamine, which is the underlying definition of PD. Having also looked at
behavioral analysis, the data is good support for a reduction in dopamine in
which geotaxis would be expected to decrease, but it should not be the only
assessment in a model of PD.

Similarly, the indirect analysis of tyrosine

hydroxylase (the rate-limiting step of dopamine) is not as accurate to determine
amount of dopamine in the brain.
Here, we hypothesize that Drosophila which has all the required biological
components to metabolize MPTP and to accumulate MPP+ in dopamine neurons
would be susceptible to MPTP(Daneman and Barres 2005). To reduce exposure
to lab personnel, we employed the CAFÉ assay to expose Drosophila rather than
food vial exposure (Ja et al 2007). Our initial results support the use of this
approach, as no aversion to the sucrose solution containing MPTP was evident
(Stafford et al. 2012). By using a visual indicator, in this case green food dye, we
compared the consumption amount of sucrose control liquid vs. MPTP liquid at
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the highest concentration used (Figure 6). We found no significant difference in
liquid consumption, when comparing the absorbance of control and exposed flies
(Figure 7).

In fact, in this case there seemed to be a slight increase in

absorbance of green dye in flies exposed to MPTP. In addition, we measured
the volume consumed in the capillary tubes before and after the CAFÉ assay.
There was also not a significant difference in the volume consumed based on an
n=5 (Figure 8).
To establish the potential of the MPTP-fly model, groups of flies were
exposed for 24 hours to increasing concentrations of MPTP (3, 6, 12, 24, or 36
mM) via the CAFÉ assay. Figure 9 indicates that brain dopamine levels were
reduced in all treated groups, except 3mM, after MPTP, when compared to
sucrose-exposed flies. We determined that 24 mM and 36 mM led to the largest
amount of dopamine loss compared to control (Figure 10A). When shown as
percent loss of dopamine (Figure 10B), 24 mM and 36 mM MPTP exposure
leads to a 40-60% dopamine loss, replicating the loss of dopamine in early
stages PD.

We determined there was no significant difference in dopamine

using the sucrose CAFÉ exposed flies compared to normal food exposed flies
(Figure 11).

This difference was a concern based on other feeding studies

showing variances in transcription due to dietary restriction (Bruce et al. 2013)
(Ding et al. 2014).
Tyrosine hydroxylase (TH), the rate-limiting step in the synthesis of
dopamine, was visualized to see if there was a deficit in dopamine-containing
neurons. After exposure to 24 mM MPTP, TH-GFP expressing neurons by the
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Gal-4 driver system (green) and co-localized with an antibody to TH (red) were
counted. It was expected that a reduction in TH would correlate with loss of
dopamine as shown in similarly exposed flies seen in the HPLC analysis. The
counts seen in the table below the images in Figure 12 show the number of TH
co-localized neurons counted. It was found that the MPTP number was lower
than the sucrose-exposed control, although this was only based on three images
per group, therefore not enough for statistical analysis.
Analysis of behavior did not result with what was expected.

We

hypothesized that a decrease in dopamine from MPTP exposure would result in
decreased climbing activity as measure by lower number of flies climbing above
7 cm (Figure 13). This hypothesis is based on other studies where drosophila
were exposed to either paraquat or rotenone and analyzed for geotaxis (Sudati et
al. 2013) (Jahromi et al. 2013). Instead, the opposite was observed where there
was an increase in climbing activity corresponding with increasing exposure to
MPTP.

Chronic studies with MPTP need to be done to test whether this

increased motor activity is due to a compensatory mechanism that won’t be
permanent.
Conclusions
In conclusion, the MPTP model in Drosophila melanogaster proposes to be a
suitable model for future investigation of mechanisms of PD pathology. This
model of exposure can be expanded for a wide range of uses for therapeutic
intervention for idiopathic and familial inherited forms of PD.
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CHAPTER THREE: AIM TWO
Correlating the inhibition of mitochondrial Complex I with the loss of the
dopaminergic system in Drosophila melanogaster: Measurement of
mitochondrial complex I activity after dose exposure to MPTP
Abstract
Dysfunction of mitochondrial complex I has been set forth as a main hypothesis
for loss of DaN in PD. There is reduction in complex I activity in PD patients and
most used neurotoxins to model PD work by inhibiting mitochondrial complex I.
Correlating an MPTP-induced death with the inhibition of mitochondrial complex I
is useful for determining the effectiveness of the model as well as establishing
the conservation of mechanisms across species.

This chapter looks at the

verification of MPTP-induced inhibition of mitochondrial complex I.
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Introduction
Parkinson's disease is associated with a systemic defect in mitochondrial
complex I activity. Animal models indicate that exposure to inhibitors of
mitochondrial complex I, including pesticides, is sufficient to reproduce the
features of PD, but genetic factors clearly modulate susceptibility. Complex I
defects may result in oxidative stress and increase the susceptibility of neurons
to excitotoxic death. In this way, environmental exposures and mitochondrial
dysfunction may interact and result in neurodegeneration.

One of the major

discoveries linking mitochondrial complex I with PD was the understanding of the
toxic mechanism associated with MPTP dopaminergic neuronal loss (Banerjee et
al. 2009).
The MPTP dosing regimen has been used in many animal models
(excluding Drosophila) and is integral in gathering more information on the
involvement of mitochondria in PD pathology. MPTP after crossing the bloodbrain barrier is metabolized to MPP+ by monoamine oxidase B and taken up by
dopaminergic neurons (DaN) by the dopamine transporter. Inside DaNs, MPTP
is accumulated in mitochondria, where it inhibits the oxidation of nicotinamide
adenine dinucleotide (NAD) substrates by blocking complex I in the electron
transport chain. This inhibited oxidation leads to a build-up of reactive oxygen
species generating damage to macromolecules.
Evaluating the activity of mitochondrial complex I in an MPTP model is key
to show the consistency of the model of PD and may allow for the identification of
a window of susceptibility to test therapeutic interventions to evaluate other
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environmental exposures that may play a role in sporadic PD.

Additionally,

establishing a timeline between complex I inhibition and susceptibility of DaN
may offer major advantage to advance evaluations with PD familial genetics that
are known to inhibit the mitochondria, such as: DJ-1, LRRK2, PINK-1, and Parkin
(Lesage and Brice 2012).
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Materials and Methods
Chemicals and Reagents
All reagents used in assessment of mitochondrial complex I activity were
purchased from Sigma Aldrich (St Louis, MO).
Fly Stocks
D. melanogaster wild-type (Canton-S) was obtained from the Bloomington Stock
center (Bloomington, IN).

The flies were reared on agar medium (1%, w/v

brewer’s yeast; 2%, w/v sucrose; 1%, w/v agar; 0.08%, v/w Tegosept) at
constant temperature and humidity (23°C; 60% relative humidity, respectively).
The flies were reared in 16 x 100 mm vials containing approximately 5 mL of
medium at constant temperature, humidity (60%) and under 12h dark/light cycle.
All experiments were performed with the same WT Canton-S strain.
Fly Exposures
The capillary feeder method (CAFE) CAFÉ assay used for exposure was
adapted from JA, et al. 2007. The exposure model used was similar with two
chambers. The inner chamber, containing the flies, was composed of a 25 cm
vial with perforated lid for air and water exchange from the outer chamber, a
1000 mL beaker with 20 cm distilled water, and additional holes for capillary tube
insertion.

Capillary tubes at 40 cm length from World Precision Instruments

(Sarasota, FL) (cat. #4878) were filled by capillary action with liquid and inserted
into the inner vial lid with an additional layer of mineral oil to prevent evaporation.
All exposures (MPTP or sucrose control) were conducted for 24 hours in a 25°C
room. After each 24-hour exposure, flies were placed back into isolation vials
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containing normal food medium for 24 hours before analyses. All exposures
were done on 5-10 day old males.
Protein Preparation
Mitochondrial and cytosolic proteins were prepared using the mitochondria
isolation kit from Abcam (Cat# ab110169). Briefly, brain from approximately 100
5-10 day-old WT male flies exposed to MPTP or 5% sucrose were dissected and
homogenized in ice cold isolation buffer containing protein inhibitor cocktail
(Roche Cat# 04693159001) using a glass dounce homogenizer. Each
homogenate was centrifuged at 1000xg at 4°C for 10 min. The supernatant was
then transferred to a new tube, and centrifuged again at 12,000xg at 4°C for 15
min to separate cytosolic and mitochondria proteins. The supernatant were
collected as the cytosolic protein sample, while the pellet was washed and resuspended in 200µl isolation buffer as the mitochondria protein sample. Protein
concentration was determined with the BCA protein Assay kit (ThermoFisher,
Cat# 23225) according to the manufacturer’s suggested protocol.
Mitochondrial Complex I Activity
Measurement of complex I activity was modeled after reagent concentrations
used in (Farge 2002).

Complex I activity was determined by following the

oxidation of NADH at 340 nm (e=6220 M–1 cm–1) using ubiquinone-1 (coenzyme
Q10) as the electron acceptor. The assay buffer consisted of 35 mM NaH2PO4
pH 7.2, 5 mM MgCl2, 2.5 mg/ml BSA, 2 mM KCN, 2 µg/ml antimycin A, 97.5 µM
ubiquinone, 0.13 mM NADH and 50 µg mitochondrial proteins. Each sample and
control was done in duplicate in a 96-well assay plate. Rotenone was added in
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duplicate to each sample as control for complete mitochondrial complex I
inhibition.
Statistical Analysis
All data were analyzed using Microsoft Excel and Prism 5 software. For
comparison of multiple groups, ANOVA was used to determine significant
differences between each group with significance of p-value >.05.
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Results
Mitochondrial Complex I activity in the Drosophila head
To further explore the impact of MPTP on the dopaminergic system in
Drosophila, we wanted to quantify the dose in which MPTP inhibits complex I of
the electron transport chain.

Three doses were chosen based on the dose-

response curve and loss of dopamine as discussed in the previous chapter
(chapter two). Figure 14, shows the results of the assessment of complex I to
reduce NADH in the presence of coenzyme Q10 by the measurement of NADH
absorbance. Each exposure group was done in duplicate and normalized to the
background of NADH.
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FIGURE 14

Figure 14. Mitochondrial Complex I activity after MPTP dose exposure
Absorbance of NADH oxidation was recorded by spectrophotometry at 430 nm.
Each exposure group was performed in duplicate and measurements were taken
every minute for 10 minutes. The higher absorbance indicates more NADH in
the assay well, due to a lack of activity of mitochondrial complex I.
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Discussion
Mitochondrial complex I is the target of MPTP-induced toxicity in dopaminergic
neurons. Determining a MPTP dose-induced inhibition of mitochondrial complex
I is important for examining a dose-susceptibility window. Here, we measured
mitochondrial complex I activity with three doses of MPTP (12, 12, and 36 mM) in
the drosophila MPTP model (Figure 14). This, to our knowledge, has not been
done before in this model.
In Figure 14, we see a dose correlated loss of activity in complex I as measured
by the absorbance of NADH. The higher absorbance of NADH is due to the lack
of oxidation by complex I from its inhibition by MPTP (24 and 36 mM MPTP).
Whereas, the control group (sucrose) and lower concentration (12 mM MPTP)
exposure we do not see an inhibition of NADH as determined by a lower
absorbance.
Conclusions
In conclusion, MPTP appears to inhibit complex I in the electron transport chain
of the mitochondria that was dose-dependent. Together, the measured damage
of MPTP, and using a dose above 24 mM proved to affect dopaminergic neurons
in the brain of Drosophila.
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APPENDIX A:
Ogg1 susceptibility to age an MPTP in Drosophila
Oxidation of the guanine base is the most common form of oxidative stressmediated damage to DNA leading to the formation and accumulation of the
modified guanine lesion 8-hydroxy-2’-deoxyguanosine (oxo8dG). Accumulation
of Oxo8dG has been linked to increased rate of mutations in dividing cells and
transcription blockage in post-mitotic cells. High levels of oxo8dG are a common
finding in affected brain areas in neurodegenerative diseases, particularly in the
SN of PD patients. Levels of oxo8dG are maintained at bay by the activity of the
DNA repair enzyme 8-oxoguanine glycosylase 1 (Ogg1). Mice lacking Ogg1
have an age-associated loss of the nigrostriatal pathway (Fernando CardozoPelaez, Sanchez-Contreras, and Nevin 2012).

This neuronal loss resembles

parkinsonian-like pathology as seen by the specific age-dependent loss of nigral
dopaminergic neurons as well as the accumulation of ubiquitin-positive inclusions
in surviving neurons of the nigrostriatal region.

Therefore, the results here

examine the susceptibility of dopamine in Ogg1 knock-out (Ogg1-/-) flies after
aging and exposure to MPTP.
Summary of Method and Results
WT Canton-S flies or Ogg1 Ogg1-/- flies were exposed to 36 mM MPTP by the
CAFÉ assay for 24 hours. After 24 hours, flies were changed to regular food and
brains were collected another 24 hours after for dopamine analysis (Figure B).
The dopamine levels were represented as percent loss compared to control,
where Ogg1-/- showed a higher percent loss compared to WT, indicating they
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may be more susceptible to MPTP. In Figure 15A, dopamine was quantified as
picograms (pg) dopamine per brain. The same analysis was performed without
exposure to MPTP, but flies were aged to 80 days.
This data is significant showing the drosophila may also have an ageassociated loss of dopamine, similar to results shown in mice. Also, Ogg1-/- flies
at a young age seem to be more susceptible to MPTP as expected.
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FIGURE 15

Figure 15. Ogg1 Dopamine Levels and susceptibility to MPTP
Dopamine level in brain of WT Canton-S flies compared to Ogg1 KO after aging
for 80 days (A). The percent dopamine loss was also compared to young WT
flies and Ogg1 KO at 36 mM MPTP for 24 hours.
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